{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:03:37Z","timestamp":1756811017032,"version":"3.41.2"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"Background<\/jats:title>For individuals with pure aortic regurgitation (AR), transcatheter aortic valve implantation (TAVI) is cautiously recommended only for those with a high or prohibitive surgical risk. We aimed to describe the results of a case series of transcatheter implantation of a balloon-expandable aortic valve bioprosthesis (BEV) for the treatment of noncalcified native valve AR.<\/jats:p><\/jats:sec>Methods<\/jats:title>From February 2022\u2013November 2022, we performed TAVI in patients with severe pure AR. Cases were indicated on the basis of symptoms, high\/prohibitive surgical risk, or patient refusal of conventional treatment.<\/jats:p><\/jats:sec>Results<\/jats:title>Five patients underwent successful TAVI. The mean age was 81.9\u2009\u00b1\u20096.6 years, 3 (60%) female and 5 (100%) in NYHA class III or IV. The baseline echocardiogram showed an ejection fraction of 49.0\u2009\u00b1\u200910.6% and left ventricular end-systolic diameter 28.5\u2009\u00b1\u20094.7\u2005mm\/m\u00b2. The average area of the aortic annulus was 529.1\u2009\u00b1\u200947.0mm\u00b2 and the area oversizing index was 17.6\u2009\u00b1\u20091.2%. In the 30-day follow-up, there were no cases of prosthesis embolization, annulus rupture, stroke, acute myocardial infarction, acute renal failure, hemorrhagic complication or death. One patient required a permanent pacemaker and another had a minor vascular complication. The clinical follow-up were 19.8 months (16.7\u201321.8). During this period, all patients remained alive and in NYHA class I or II. One of the patients developed a moderate paravalvular leak.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>TAVI with a BEV proved to be safe and effective in this small case series of patients with noncalcified native valve AR in a follow-up longer than 1 year.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1365181","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:56:17Z","timestamp":1714107377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Transcatheter aortic valve implantation using balloon-expandable bioprosthesis in patients with severe pure aortic regurgitation on noncalcified native valves: a series of cases"],"prefix":"10.3389","volume":"11","author":[{"given":"Luciano de Moura","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Santos","family":"Luz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius Lelis","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulio Assun\u00e7\u00e3o","family":"Barcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico Andr\u00e9 Alves","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Cogo","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Jamal Aldin Hilal","family":"Darnasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco de Assis","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Carlos Vieira","family":"Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Wenderval Borges","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1161\/CIRCULATIONAHA.119.041080","article-title":"Contemporary presentation and management of valvular heart disease","volume":"140","author":"Iung","year":"2019","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIR.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.jcin.2016.08.049","article-title":"Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation","volume":"9","author":"Franzone","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.amjcard.2018.05.044","article-title":"Usefulness of transcatheter aortic valve implantation for treatment of pure native aortic valve regurgitation","volume":"122","author":"De Backer","year":"2018","journal-title":"Am J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.15420\/icr.2018.37.1","article-title":"TAVI for pure native aortic regurgitation: are we there yet?","volume":"14","author":"Arias","year":"2019","journal-title":"Interv Cardiol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.hlc.2019.04.012","article-title":"Meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation","volume":"29","author":"Takagi","year":"2020","journal-title":"Heart Lung Circ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/atm-21-6936","article-title":"Outcomes of transcatheter aortic valve replacement for pure native aortic regurgitation with the use of newer- vs. early-generation devices","volume":"10","author":"Yin","year":"2022","journal-title":"Ann Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ccd.30529","article-title":"Overinflation of balloon-expandable valves for transcatheter treatment of pure noncalcified native aortic regurgitation: how much oversizing is needed and achievable?","volume":"101","author":"Orzalkiewicz","year":"2023","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1365181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:56:21Z","timestamp":1714107381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1365181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":9,"alternative-id":["10.3389\/fcvm.2024.1365181"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1365181","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"article-number":"1365181"}}